NCT03769467 2024-11-14Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)Atara BiotherapeuticsPhase 1/2 Terminated12 enrolled 8 charts